GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on ...
A routine blood test identified abnormalities, leading to follow-up tests. A hematologist diagnosed Evans with early-stage ...
Erdafitinib showed a predictable toxicity profile and early efficacy in IDH–wild-type glioma with FGFR-TACC fusions. The recommended phase 2 dose was 8 mg daily, with one grade 3 central serous ...
Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.
A new study suggests that hydrogen sulfide, a gas released by the body when you fart, could help protect the brain against ...
Tolebrutinib received provisional approval in the United Arab Emirates in July 2025 for non-relapsing secondary progressive ...
US FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab for 1st-line treatment of patients with HER2-positive metastatic breast cancer: Cambridge, UK Wednesday, ...
Sanofi’s PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis fails to meet primary endpoint: Paris Tuesday, December 16, 2025, 11:00 Hrs [IST] Sanofi ...
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosisPERSEUS phase 3 study in primary progressive multiple sclerosis ...
Tolebrutinib received provisional approval in the United Arab Emirates in July 2025 for non-relapsing secondary progressive multiple sclerosis. The drug is currently under regulatory review in the EU ...
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback